logo
NYSE:ADCT logo

ADC Therapeutics Community

NYSE:ADCT Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

ADCT logo
ADC Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts

Expanding ZYNLONTA Trials Will Broaden DLBCL Treatment Options

Key Takeaways Expanding ZYNLONTA into earlier lines of DLBCL through trials could significantly boost revenue by accessing a larger patient population. Strategic advancements and research collaborations are poised to enhance profitability and strengthen long-term growth prospects.
View narrative
US$8.20
FV
82.7% undervalued intrinsic discount
28.19%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
6 days ago author updated this narrative